MARKET

IMUX

IMUX

Immunic Inc
NASDAQ
0.6500
-0.0273
-4.03%
After Hours: 0.6599 +0.0099 +1.52% 19:58 01/14 EST
OPEN
0.6634
PREV CLOSE
0.6773
HIGH
0.6871
LOW
0.6298
VOLUME
1.78M
TURNOVER
--
52 WEEK HIGH
1.390
52 WEEK LOW
0.5062
MARKET CAP
78.19M
P/E (TTM)
-0.7773
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at IMUX last week (0105-0109)?
Weekly Report · 2d ago
Immunic Buy Rating: Undervalued Next-Generation Oral MS Therapy with Key Phase III Catalysts and Strategic Partnership Upside
TipRanks · 01/07 21:15
Immunic Price Target Maintained With a $8.00/Share by D. Boral Capital
Dow Jones · 01/07 14:06
Immunic Is Maintained at Buy by D. Boral Capital
Dow Jones · 01/07 14:06
D. Boral Capital Maintains Buy on Immunic, Maintains $8 Price Target
Benzinga · 01/07 13:57
Immunic Transfers Listing to Nasdaq Capital Market for Compliance
TipRanks · 01/06 21:33
Immunic Inc. Faces Nasdaq Delisting Risk Over Continued Low Share Price
Reuters · 01/06 21:06
Immunic Inc. Sets New CEO Pay Package for Duane Nash
Reuters · 01/05 22:01
More
About IMUX
Immunic, Inc. is a biotechnology company developing a clinical pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The Company is engaged in pursuing clinical development of programs, which include the vidofludimus calcium (IMU-838) program, which is in Phase III clinical development for patients with relapsing multiple sclerosis (RMS), and which has shown therapeutic activity in Phase II clinical trials in patients suffering from relapsing-remitting MS, progressive MS and moderate-to-severe ulcerative colitis; the IMU-856 program, which is targeted to regenerate bowel epithelium and restore intestinal barrier function, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, Graft-versus-Host-Disease and weight management, and the IMU-381 program, which is a molecule being developed to specifically address the needs of gastrointestinal diseases.

Webull offers Immunic Inc stock information, including NASDAQ: IMUX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMUX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IMUX stock methods without spending real money on the virtual paper trading platform.